Joseph Ross

1 month ago | bmj.com | Alexander O. Everhart |Pinar Karaca-Mandic |Rita F. Redberg |Joseph Ross

Research BMJ 2025; 388 doi: https://doi.org/10.1136/bmj-2024-081518 Cite this as: BMJ 2025;388:e081518 Alexander O Everhart, instructor1 2, Pinar Karaca-Mandic, professor3, Rita F Redberg, professor4 5, Joseph S Ross, professor6 7 8, Sanket S Dhruva, associate professor9 10 11 1Division of General Medical Sciences, John T Milliken Department of Medicine, Washington University School of Medicine in St Louis, St Louis, MO, USA 2Center for Advancing Health Services, Policy and Economics...

Nov 15, 2024 | jamanetwork.com | Osman Moneer |James Johnston |Vinay K. Rathi |Joseph Ross

Key PointsQuestion  What evidence do the Centers for Medicare & Medicaid Services (CMS) consider when approving or denying transitional pass-through payments (TPTPs) for new outpatient medical devices? Findings  This cross-sectional study of 43 TPTP applications from 2017 to 2023 found that CMS approved 17 (40%), including all 8 (100%) applications for US Food and Drug Administration (FDA)-designated breakthrough devices.

Oct 21, 2024 | jamanetwork.com | Linda Brubaker |Gregory Curfman |Joseph Ross

The outcome of the 2024 US election will undoubtedly affect patient and community health, along with the health care delivery system, in a multitude of ways.

Aug 27, 2024 | jamanetwork.com | Maryam Mooghali |Yale Collaboration |Joshua D. Wallach |Joseph Ross

Key PointsQuestion  What are the premarket end points and postmarketing requirements for US Food and Drug Administration (FDA) breakthrough therapy–designated approvals? Findings  In this cross-sectional study of 157 original indications with breakthrough therapy designation, all accelerated approvals and 58% of traditional approvals were based on pivotal trials using surrogate markers as primary end points.

Jul 26, 2024 | jamanetwork.com | Seth Zissette |Anant Gautam |Harlan M. Krumholz |Joseph Ross

Introduction Use of preprints, defined as preliminary research reports that have not undergone peer review, in clinical and health science research has increased in recent years, partly because of the COVID-19 pandemic.1,2 Although high-impact clinical journals have publication policies supportive of preprints,3 concerns remain that posting a preprint before submission to a peer-reviewed journal may jeopardize publication, especially if the preprint generates media attention and citations.4...